Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries

Bulletin of the World Health Organization

Volumn 89, Issue 6, 2011, Pages 412-421

  Cameron, Alexandra ^a   Roubos, Ilse ^b   Ewen, Margaret ^c   Mantel Teeuwisse, Aukje K ^b   Leufkens, Hubertus G M ^b   Laing, Richard O ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Vancouver BC   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALBENDAZOLE; AMITRIPTYLINE; AMOXICILLIN; ANTIASTHMATIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; CAPTOPRIL; CARBAMAZEPINE; CEFALEXIN; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; DIAZEPAM; DICLOFENAC; ERYTHROMYCIN; FLUCONAZOLE; GENERIC DRUG; GLIBENCLAMIDE; IBUPROFEN; MEBENDAZOLE; METFORMIN; METRONIDAZOLE; OMEPRAZOLE; PYRIMETHAMINE PLUS SULFADOXINE; RANITIDINE; SALBUTAMOL; UNINDEXED DRUG;

DEVELOPING WORLD; DISEASE TREATMENT; MEDICINE; PRIVATE SECTOR; PUBLIC SECTOR; WORLD BANK; WORLD HEALTH ORGANIZATION;

ACUTE DISEASE; ARTICLE; CHRONIC DISEASE; DEVELOPING COUNTRY; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; PUBLIC HEALTH; SOCIOECONOMICS;

ACUTE DISEASE; CHRONIC DISEASE; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; DEVELOPING COUNTRIES; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; PRESCRIPTION DRUGS; PRIVATE SECTOR; PUBLIC SECTOR; STATISTICS AS TOPIC;

EID: 79958068487     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.10.084327     Document Type: Article

References (40)

1. Preventing chronic diseases: a vital investment. Geneva: World Health Organization; 2005.
2. The global burden of disease: 2004 update. Geneva: World Health Organization; 2008. Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf [accessed 4 March 2011].
3. Strong K, Mathers C, Leeder S, Beaglehole R. Preventing chronic diseases: how many lives can we save? Lancet 2005;366:1578-82. doi:10.1016/S0140-6736(05)67341-2 PMID:16257345
4. 2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases. Geneva: World Health Organization; 2008. Available from: http://www.who.int/nmh/Actionplan-PC-NCD-2008.pdf [accessed 4 March 2011].
5. Prevention of recurrent heart attacks and strokes in low and middle income populations: evidence-based recommendations for policy-makers and health professionals. Geneva: World Health Organization; 2003.
6. Mitchell EA, Didsbury PB, Kruithof N, Robinson E, Milmine M, Barry M et al. A randomized controlled trial of an asthma clinical pathway for children in general practice. Acta Paediatr 2005;94:226-33. doi:10.1080/08035250410020235 PMID:15981759
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53. doi:10.1016/S0140-6736(98)07019-6 PMID:9742976
8. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;3:CD002966. PMID:16034881
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86. doi:10.1056/NEJM199309303291401 PMID:8366922
10. The global partnership for development at a critical juncture: MDG Gap Task Force Report 2010. New York: United Nations; 2010.
11. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 2009;373:240-9. doi:10.1016/S0140-6736(08)61762-6 PMID:19042012
12. Strengthening the global partnership for development in a time of crisis: MDG Gap Task Force Report 2009. New York: United Nations; 2009.
13. Sooksriwong C, Yoongthong W, Suwattanapreeda S, Chanjaruporn F. Medicine prices in Thailand: a result of no medicine pricing policy. Southern Med Review 2009;2:10-4.
14. Nguyen AT, Knight R, Mant A, Cao QM, Auton M. Medicine prices, availability, and affordability in Vietnam. Southern Med Review 2009;2:2-9.
15. Kotwani A, Gurbani N, Sharma S, Chaudhury RR. Insights for policymakers from a medicine price survey in Rajasthan. Indian J Med Res 2009;129:451-4. PMID:19535843
16. Delivering on the global partnership for achieving the Millennium Development Goals: MDG Gap Task Force Report 2008. New York: United Nations; 2008.
17. Medicine prices, availability, affordability and price components. A synthesis report of medicine price surveys undertaken in selected countries of the WHO Eastern Mediterranean Region. Cairo: WHO Regional Office for the Eastern Mediterranean; 2008.
18. Babar ZUD, Ibrahim MIM, Singh H, Bukahri NI, Creese A. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med 2007;4:e82. doi:10.1371/journal.pmed.0040082 PMID:17388660
19. van Mourik MS, Cameron A, Ewen M, Laing RO. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord 2010;10:25. doi:10.1186/1471-2261-10-25 PMID:20534118
20. Chomba EN, Haworth A, Mbewe E, Atadzhanov M, Ndubani P, Kansembe H et al. The current availability of antiepileptic drugs in Zambia: implications for the ILAE/WHO "out of the shadows" campaign. Am J Trop Med Hyg 2010;83:571-4. doi:10.4269/ajtmh.2010.10-0100 PMID:20810822
21. Kotwani A. Availability, price and affordability of asthma medicines in five Indian states. Int J Tuberc Lung Dis 2009;13:574-9. PMID:19383189
22. Higuchi M. Costs, availability and affordability of diabetes care in the Philippines. Tokyo: Foundation for Advanced Studies on International Development; 2009. Available from: http://www.fasid.or.jp/chosa/jyosei/list_pdf/19-1-e.pdf. [accessed 4 March 2011].
23. Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ 2007;85:279-88. doi:10.2471/BLT.06.033647 PMID:17546309
24. Gelders S, Ewen M, Noguchi N, Laing R. Price, availability and affordability: an international comparison of chronic disease medicines. Cairo: World Health Organization Regional Office for the Eastern Mediterranean; 2006.
25. Mac TL, Le VT, Vu AN, Preux PM, Ratsimbazafy V. AEDs availability and professional practices in delivery outlets in a city center in southern Vietnam. Epilepsia 2006;47:330-4. doi:10.1111/j.1528-1167.2006.00425.x PMID:16499757
26. Medicine prices: a new approach to measurement, 2003 edition. Working draft for field testing and revision. Geneva: World Health Organization & Health Action International; 2003. Available from: http://whqlibdoc.who.int/hq/2003/WHO_EDM_PAR_2003.2.pdf [accessed 4 March 2011].
27. Measuring medicine prices, availability, affordability and price components. 2nd ed. Geneva: World Health Organization & Health Action International; 2008. Available from: http://www.haiweb.org/medicineprices/manual/documents.html [accessed 4 March 2011].
28. Madden JM, Meza E, Ewen M, Laing RO, Stephens P, Ross-Degnan D. Measuring medicine prices in Peru: validation of key aspects of WHO/HAI survey methodology. Rev Panam Salud Publica 2010;27:291-9. doi:10.1590/S1020-49892010000400008 PMID:20512232
29. Medicine prices [Internet]. Amsterdam: Health Action International; 2007. Available from: http://www.haiweb.org/medicineprices/ [accessed 4 March 2011].
30. Country classification [Internet]. Washington: The World Bank Group; 2007. Available from: www.worldbank.org/data/countryclass/classgroups.htm [accessed 4 March 2011].
31. GINI index [Internet]. Washington: The World Bank Group; 2011. Available from: http://data.worldbank.org/indicator/SI.POV.GINI [accessed 4 March 2011].
32. International language for drug utilization research [Internet]. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health. [updated 2009 Nov 19]. Available from: http://www.whocc.no/ [accessed 9 March 2011].
33. Plan M-TS. 2008-2013 [Internet]. Geneva: World Health Organization; 2008. Available from: http://apps.who.int/gb/e/e_amtsp.html [accessed 4 March 2011].
34. Niëns LM, Cameron A, Van de Poel E, Ewen M, Brouwer WBF, Laing R. Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. PLoS Med 2010;7:1-8. doi:10.1371/journal.pmed.1000333 PMID:20824175
35. Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJL. Household catastrophic health expenditure: a multicountry analysis. Lancet 2003;362:111-7. doi:10.1016/S0140-6736(03)13861-5 PMID:12867110
36. CDAP Overview [Internet]. Port-of-Spain: Ministry of Health, Government of the Republic of Trinidad and Tobago; 2010. Available from: http://www.health.gov.tt/sitepages/default.aspx?id=132 [accessed 4 March 2011].
37. National Health Fund of Jamaica [Internet]. Kingston: National Health Fund; 2009. Available from: http://www.nhf.org.jm/index.php [accessed 4 March 2011].
38. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006;296:679-90. doi:10.1001/jama.296.6.679 PMID:16896111
39. 2008 UNAIDS annual report: towards universal access. Geneva: Joint United Nations Programme on HIV/AIDS; 2009. Available from: http://data.unaids.org/pub/Report/2009/jc1736_2008_annual_report_en.pdf [accessed 4 March 2011].
40. Yach D, Hawkes C, Epping-Jordan J, Steyn K. Chronic diseases and risks. In: Merson MH, Black RE, Mills A, editors. International public health: diseases, programs, systems, and policies. 2nd ed. Sudbury: Jones & Bartlett Publishers, Inc.; 2006.